Jaguar Health利用病人报告的结果,为乳腺癌腹泻研究提供摘要。 Jaguar Health submits abstract for breast cancer diarrhea study using patient-reported outcomes.

Jaguar Health 为一项研究提交了一份摘要，该研究评估了 OnTarget 3 期试验中癌症治疗对乳腺癌患者引起的腹泻。 Jaguar Health has submitted an abstract for a study assessing diarrhea caused by cancer therapies in breast cancer patients from the OnTarget Phase 3 trial. 该研究涉及142名病人,包括75名乳腺癌患者,通过数字应用利用病人报告的结果。 The research, involving 142 patients, including 75 with breast cancer, utilizes patient-reported outcomes via digital applications. 这项研究可能是第一份记录直接来自病人的胃肠症状的研究报告,目的是加强对癌症治疗腹泻病的理解和管理。 This study may be the first to document gastrointestinal symptoms directly from patients, aiming to enhance understanding and management of cancer therapy-related diarrhea (CTD).